This Week in Urology — Oct 30, 2026
Generated Oct 30, 2026 · 10:54
The week's practice-changing Urology research, summarized for clinicians.
If the audio fails to play, refresh the page to renew the link.
Get next week’s Urology briefing — free.
In your podcast app, or readable in your inbox with the audio one tap away.
Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer.
In cisplatin-ineligible muscle-invasive bladder cancer, perioperative durvalumab plus neoadjuvant enfortumab vedotin roughly halved event risk and improved overall survival versus cystectomy alone, at the cost of frequent severe toxicity.
New England Journal of Medicine · 2026 · PubMed
This week’s papers
- 01
Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer.
In cisplatin-ineligible muscle-invasive bladder cancer, perioperative durvalumab plus neoadjuvant enfortumab vedotin roughly halved event risk and improved overall survival versus cystectomy alone, at the cost of frequent severe toxicity.
Powles T, Grande E, Simone G, et al. · New England Journal of Medicine · 2026
From the briefingIn the New England Journal of Medicine, Powles and colleagues report the phase 3 VOLGA trial, which randomized nearly 700 cisplatin-ineligible or cisplatin-declining patients to one of three arms: neoadjuvant durvalumab with enfortumab vedotin for three cycles, then cystectomy and adjuvant durvalumab; the same approach with tremelimumab added; or cystectomy alone [1]. At two years, event-free survival was about 64 percent with durvalumab plus enfortumab vedotin versus about 45 percent with surgery alone, roughly halving the risk of an event or death. Overall survival also improved, to about 78 percent versus about 69 percent, a reduction in the risk of death of around 40 percent. The triplet arm with tremelimumab also beat surgery on event-free survival, though overall survival was the key secondary endpoint and the trial did not compare the two drug arms with each other. The cost is toxicity: grade 3 or higher adverse events of any cause occurred in about 71 percent of patients on the doublet and close to 80 percent on the triplet, against about half of patients in the surgery-only arm, with treatment-related severe events in roughly a third and nearly half of patients respectively. The trial was open-label and industry-funded, but with a survival advantage in a population that previously had no proven perioperative systemic therapy, it substantially strengthens the case for this regimen in cisplatin-ineligible patients.
If you only have time for one paper this week, make it the VOLGA trial in the New England Journal of Medicine [1]. It is the first phase 3 evidence of a survival benefit from perioperative systemic therapy for cisplatin-ineligible muscle-invasive bladder cancer, reopening the question of whether surgery alone remains acceptable for these patients.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 02
Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.
Adding the GDF-15 antibody visugromab to neoadjuvant nivolumab raised pathologic complete response from 8 to 33 percent in 31 cisplatin-ineligible bladder cancer patients, an early nonrandomized signal.
Necchi A, Mercinelli C, Maiorano BA, et al. · Nature Medicine · 2026
From the briefingAlongside it, in Nature Medicine, Necchi and colleagues report the much earlier GDFATHER-NEO study, a nonrandomized, placebo-controlled phase 2a trial in 31 similar patients testing whether blocking growth differentiation factor 15 with visugromab could overcome resistance to PD-1 blockade [2]. Pathologic complete response was 33 percent with nivolumab plus visugromab versus 8 percent with nivolumab plus placebo, and radiographic response rose from about 15 percent to 60 percent, with no treatment-related surgical delays. These are tiny numbers with wide uncertainty, and responses tracked with baseline CD8 T-cell density rather than PD-L1 status or GDF-15 levels, so this is a hypothesis-generating signal rather than anything approaching practice change.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 03
Advances in the management of renal cell carcinoma.
Renal cell carcinoma care now combines nephrectomy or ablation for localized disease, adjuvant pembrolizumab for high-risk clear cell tumours, and immunotherapy combinations for metastases, though biomarkers remain lacking.
Lewis AR, Lyon TD, Gupta S, et al. · BMJ · 2026
From the briefingIn the BMJ, Lewis and colleagues provide a clinical review of renal cell carcinoma, noting that nephrectomy remains standard for localized disease, that ablation or stereotactic radiation suits selected patients, and that adjuvant pembrolizumab improves both disease-free and overall survival in high-risk clear cell disease, while resistance and the lack of predictive biomarkers remain the central problems [3].
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 04
A Trial-Level Benefit-Toxicity Mapping Framework for Adjuvant Therapy in Renal Cell Carcinoma: A Focused Review.
Across ten adjuvant kidney cancer trial programs, benefit was inconsistent and toxicity substantial, with newer immunotherapy combinations showing disease-free survival signals but discontinuation in about a third of patients.
Shinohara M, Narita T, Hatakeyama S · International Journal of Urology · 2026
From the briefingShinohara and colleagues, in the International Journal of Urology, take that adjuvant story apart trial by trial with a descriptive benefit-toxicity mapping framework across ten adjuvant programs [4]. Tyrosine kinase inhibitor trials showed limited and inconsistent benefit, with only S-TRAC meeting its endpoint, while severe adverse events affected roughly 60 to 70 percent of patients. Among immunotherapy trials, KEYNOTE-564 was positive while IMmotion010 and CheckMate 914 Part A were negative, and newer combinations in RAMPART and LITESPARK-022 showed disease-free survival signals but with treatment discontinuation for adverse events in about a third of patients. The authors are explicit that this is not a cross-trial ranking, but the framework is a useful counselling lens, and it echoes the VOLGA lesson that perioperative benefit increasingly comes bundled with substantial toxicity.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 05
Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference.
An international expert panel reached consensus on only about a third of 134 questions on high-risk, locally advanced and recurrent prostate cancer, highlighting major evidence gaps needing trials.
Gillessen S, Turco F, Davis ID, et al. · European Urology · 2026
From the briefingIn European Urology, Gillessen and colleagues report the 2026 Advanced Prostate Cancer Consensus Conference voting on high-risk localized, locally advanced, and biochemically recurrent disease [5]. Of 134 questions put to 133 international panellists, consensus was reached on only about a third, with just seven reaching strong consensus. That is expert opinion without formal literature review, and its main value may be in mapping the gaps, including PSA persistence and recurrence, where dedicated trials are needed.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 06
A Randomized Trial of Multimodal Prehabilitation Before Robotic-Assisted Radical Prostatectomy to Improve Postoperative Quality of Life and Functional Outcomes.
Four weeks of multimodal prehabilitation before robotic prostatectomy improved one-month quality of life, mental health and continence in a single-centre trial, though the global benefit attenuated by six months.
Carbonell E, Dana F, Tena B, et al. · The Journal of Urology · 2026
From the briefingOn the recovery side, Carbonell and colleagues in The Journal of Urology randomized 100 men before robotic prostatectomy to a four-week multimodal prehabilitation program of physical and pelvic floor training, nutritional counselling and psychological support, or usual care [6]. One month after surgery, global health status was about 15 points higher on a 100-point scale with prehabilitation, with better mental health and continence scores. That quality-of-life advantage faded to about four and a half points by six months, though continence and mental health gains persisted, and there was no difference in physical performance or erectile function. The authors argue for routine integration, but this is a single-centre trial with modest numbers, so the evidence supports prehabilitation as beneficial for early recovery while falling short of definitive.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 07
Bipolar Enucleation of the Prostate Versus Transurethral Resection of the Prostate: A Prospective Randomized Controlled Noninferiority Trial.
Bipolar enucleation was noninferior to transurethral resection for 12-month symptom relief in moderate-sized prostates, removing more tissue with more minor but no major early complications.
Pallauf M, Oswald D, Ramesmayer C, et al. · European Urology Focus · 2026
From the briefingIn European Urology Focus, Pallauf and colleagues report a two-centre randomized noninferiority trial of 84 men with prostates of 40 to 150 millilitres, comparing bipolar enucleation with transurethral resection [7]. At 12 months, the median symptom score was five in both arms, meeting noninferiority. Enucleation removed more tissue, about 38 versus 25 grams, despite roughly 20 minutes longer operating time. Minor complications in the first month were more common after enucleation, at about half of patients versus about a quarter, whereas major complications occurred only after resection, in about one in ten patients. The per-protocol analysis included roughly four in five randomized men and follow-up is short, so this supports bipolar enucleation as a reasonable alternative, pending longer-term data.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 08
Initiation of Medical Therapy for Storage Lower Urinary Tract Symptoms After Benign Prostatic Hyperplasia Surgery.
In over 11,000 Michigan patients, new anticholinergic or beta-3 agonist use after BPH surgery ranged from about 6 to 11 percent, highest after photovaporization.
Uy M, DiBianco JM, Mansour S, et al. · The Journal of Urology · 2026
From the briefingComplementing that, Uy and colleagues in The Journal of Urology used Michigan statewide claims on more than 11,000 medication-naive men to estimate how often patients start an anticholinergic or beta-3 agonist for storage symptoms after outlet surgery [8]. Twelve-month initiation ranged from about 6 percent after microwave thermotherapy to 11 percent after photovaporization, which carried roughly a 50 percent higher hazard than resection. Prior BPH medication and anticoagulation were linked to higher initiation, catheter dependence to lower. As observational claims data, it cannot establish cause, but it offers real-world benchmarks for preoperative counselling.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 09
Surgery in Motion: Different Surgical Techniques for Inguinal Lymph Node Dissection in Penile Cancer.
Open inguinal lymph node dissection remains the reference for penile cancer, while video-endoscopic and robotic approaches may reduce morbidity in selected limited-nodal-disease patients at experienced centres.
Verdijk RWA, Patterson K, Brassetti A, et al. · European Urology · 2026
From the briefingIn European Urology, a Surgery in Motion article reviews open, video-endoscopic and robot-assisted inguinal lymph node dissection, concluding that open dissection remains the reference, particularly for advanced nodal disease, while minimally invasive approaches may suit selected patients with limited nodal disease at experienced centres [9].
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 10
Dynamic Sentinel Lymph Node Biopsy (DSNB) in Penile Cancer: A Practical Guide for Clinical Implementation.
Reliable dynamic sentinel node biopsy in penile cancer depends on a standardised multidisciplinary workflow with nuclear medicine and radioguided surgery expertise, outlined as minimum technical requirements.
Verdijk RWA, van der Poel HG, Brouwer OR · European Urology Focus · 2026
From the briefingIn European Urology Focus, a companion practical guide sets out minimum requirements for dynamic sentinel node biopsy, emphasising a standardised multidisciplinary workflow with nuclear medicine expertise [10]. Neither presents new outcome data, but together they frame sentinel node biopsy and minimally invasive dissection as tools to reduce morbidity in a disease where expertise is concentrated.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
The full briefing
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Urology. This week we're covering 10 notable papers spanning perioperative immunotherapy in bladder and kidney cancer, decision-making and recovery in prostate cancer, and the surgical craft of benign prostatic and penile cancer care. Let's dive in.
The biggest story this week is in muscle-invasive bladder cancer, where patients who cannot receive cisplatin have long had few options beyond going straight to cystectomy. In the New England Journal of Medicine, Powles and colleagues report the phase 3 VOLGA trial, which randomized nearly 700 cisplatin-ineligible or cisplatin-declining patients to one of three arms: neoadjuvant durvalumab with enfortumab vedotin for three cycles, then cystectomy and adjuvant durvalumab; the same approach with tremelimumab added; or cystectomy alone [1]. At two years, event-free survival was about 64 percent with durvalumab plus enfortumab vedotin versus about 45 percent with surgery alone, roughly halving the risk of an event or death. Overall survival also improved, to about 78 percent versus about 69 percent, a reduction in the risk of death of around 40 percent. The triplet arm with tremelimumab also beat surgery on event-free survival, though overall survival was the key secondary endpoint and the trial did not compare the two drug arms with each other. The cost is toxicity: grade 3 or higher adverse events of any cause occurred in about 71 percent of patients on the doublet and close to 80 percent on the triplet, against about half of patients in the surgery-only arm, with treatment-related severe events in roughly a third and nearly half of patients respectively. The trial was open-label and industry-funded, but with a survival advantage in a population that previously had no proven perioperative systemic therapy, it substantially strengthens the case for this regimen in cisplatin-ineligible patients. Alongside it, in Nature Medicine, Necchi and colleagues report the much earlier GDFATHER-NEO study, a nonrandomized, placebo-controlled phase 2a trial in 31 similar patients testing whether blocking growth differentiation factor 15 with visugromab could overcome resistance to PD-1 blockade [2]. Pathologic complete response was 33 percent with nivolumab plus visugromab versus 8 percent with nivolumab plus placebo, and radiographic response rose from about 15 percent to 60 percent, with no treatment-related surgical delays. These are tiny numbers with wide uncertainty, and responses tracked with baseline CD8 T-cell density rather than PD-L1 status or GDF-15 levels, so this is a hypothesis-generating signal rather than anything approaching practice change.
Kidney cancer brings a similar perioperative question into focus: how much toxicity is worth how much benefit. In the BMJ, Lewis and colleagues provide a clinical review of renal cell carcinoma, noting that nephrectomy remains standard for localized disease, that ablation or stereotactic radiation suits selected patients, and that adjuvant pembrolizumab improves both disease-free and overall survival in high-risk clear cell disease, while resistance and the lack of predictive biomarkers remain the central problems [3]. Shinohara and colleagues, in the International Journal of Urology, take that adjuvant story apart trial by trial with a descriptive benefit-toxicity mapping framework across ten adjuvant programs [4]. Tyrosine kinase inhibitor trials showed limited and inconsistent benefit, with only S-TRAC meeting its endpoint, while severe adverse events affected roughly 60 to 70 percent of patients. Among immunotherapy trials, KEYNOTE-564 was positive while IMmotion010 and CheckMate 914 Part A were negative, and newer combinations in RAMPART and LITESPARK-022 showed disease-free survival signals but with treatment discontinuation for adverse events in about a third of patients. The authors are explicit that this is not a cross-trial ranking, but the framework is a useful counselling lens, and it echoes the VOLGA lesson that perioperative benefit increasingly comes bundled with substantial toxicity.
In prostate cancer, two very different papers address areas where evidence is thin. In European Urology, Gillessen and colleagues report the 2026 Advanced Prostate Cancer Consensus Conference voting on high-risk localized, locally advanced, and biochemically recurrent disease [5]. Of 134 questions put to 133 international panellists, consensus was reached on only about a third, with just seven reaching strong consensus. That is expert opinion without formal literature review, and its main value may be in mapping the gaps, including PSA persistence and recurrence, where dedicated trials are needed. On the recovery side, Carbonell and colleagues in The Journal of Urology randomized 100 men before robotic prostatectomy to a four-week multimodal prehabilitation program of physical and pelvic floor training, nutritional counselling and psychological support, or usual care [6]. One month after surgery, global health status was about 15 points higher on a 100-point scale with prehabilitation, with better mental health and continence scores. That quality-of-life advantage faded to about four and a half points by six months, though continence and mental health gains persisted, and there was no difference in physical performance or erectile function. The authors argue for routine integration, but this is a single-centre trial with modest numbers, so the evidence supports prehabilitation as beneficial for early recovery while falling short of definitive.
Benign prostatic surgery had two informative papers. In European Urology Focus, Pallauf and colleagues report a two-centre randomized noninferiority trial of 84 men with prostates of 40 to 150 millilitres, comparing bipolar enucleation with transurethral resection [7]. At 12 months, the median symptom score was five in both arms, meeting noninferiority. Enucleation removed more tissue, about 38 versus 25 grams, despite roughly 20 minutes longer operating time. Minor complications in the first month were more common after enucleation, at about half of patients versus about a quarter, whereas major complications occurred only after resection, in about one in ten patients. The per-protocol analysis included roughly four in five randomized men and follow-up is short, so this supports bipolar enucleation as a reasonable alternative, pending longer-term data. Complementing that, Uy and colleagues in The Journal of Urology used Michigan statewide claims on more than 11,000 medication-naive men to estimate how often patients start an anticholinergic or beta-3 agonist for storage symptoms after outlet surgery [8]. Twelve-month initiation ranged from about 6 percent after microwave thermotherapy to 11 percent after photovaporization, which carried roughly a 50 percent higher hazard than resection. Prior BPH medication and anticoagulation were linked to higher initiation, catheter dependence to lower. As observational claims data, it cannot establish cause, but it offers real-world benchmarks for preoperative counselling.
Finally, penile cancer nodal management received two educational contributions from Verdijk and colleagues. In European Urology, a Surgery in Motion article reviews open, video-endoscopic and robot-assisted inguinal lymph node dissection, concluding that open dissection remains the reference, particularly for advanced nodal disease, while minimally invasive approaches may suit selected patients with limited nodal disease at experienced centres [9]. In European Urology Focus, a companion practical guide sets out minimum requirements for dynamic sentinel node biopsy, emphasising a standardised multidisciplinary workflow with nuclear medicine expertise [10]. Neither presents new outcome data, but together they frame sentinel node biopsy and minimally invasive dissection as tools to reduce morbidity in a disease where expertise is concentrated.
If you only have time for one paper this week, make it the VOLGA trial in the New England Journal of Medicine [1]. It is the first phase 3 evidence of a survival benefit from perioperative systemic therapy for cisplatin-ineligible muscle-invasive bladder cancer, reopening the question of whether surgery alone remains acceptable for these patients.
Here is what this week's evidence adds up to in Urology. First, perioperative durvalumab with enfortumab vedotin improved both event-free and overall survival over cystectomy alone in cisplatin-ineligible bladder cancer, based on a single large open-label trial, with severe toxicity in most treated patients; GDF-15 blockade remains an early signal from a very small study. Second, adjuvant therapy in kidney cancer shows inconsistent benefit across trials and meaningful toxicity, and trial-level mapping suggests weighing both rather than disease-free survival alone. Third, in high-risk and recurrent prostate cancer, expert consensus covers only about a third of key questions, and prehabilitation improved early recovery in one single-centre trial, with benefits partly fading by six months. Fourth, bipolar enucleation matched resection for symptom relief at one year in a small trial, and new storage medication after BPH surgery is uncommon but varies by procedure. Longer follow-up and confirmatory data remain the open questions across nearly all of these areas.
That's your roundup for This Week in Urology. The full transcript and references are available on the episode page. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if it saves you time, a quick rating in your podcast app helps other physicians find the show.
This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.
Spot something worth flagging?
Get this every week in your podcast app — free.
New urology episodes land in your feed automatically — listen on your commute.